Review



tissuescan cdna arrays containing 26 samples from patients with dlbcl and 10 normal lymphoid tissue controls  (OriGene)


Bioz Verified Symbol OriGene is a verified supplier
Bioz Manufacturer Symbol OriGene manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    OriGene tissuescan cdna arrays containing 26 samples from patients with dlbcl and 10 normal lymphoid tissue controls
    <t>(A)</t> <t>qRT-PCR</t> analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and <t>DLBCL</t> cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.
    Tissuescan Cdna Arrays Containing 26 Samples From Patients With Dlbcl And 10 Normal Lymphoid Tissue Controls, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+cdna+sample/Tissue+FFPE+Sections%2C+Lymphoid+tissue/pmc05272186-675-4-24
    Average 90 stars, based on 1 article reviews
    tissuescan cdna arrays containing 26 samples from patients with dlbcl and 10 normal lymphoid tissue controls - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "BCL-W has a fundamental role in B cell survival and lymphomagenesis"

    Article Title: BCL-W has a fundamental role in B cell survival and lymphomagenesis

    Journal: The Journal of Clinical Investigation

    doi: 10.1172/JCI89486

    (A) qRT-PCR analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and DLBCL cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.
    Figure Legend Snippet: (A) qRT-PCR analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and DLBCL cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.

    Techniques Used: Quantitative RT-PCR, Microarray, Expressing, Immunohistochemical staining, Whisker Assay, Staining, Western Blot, Purification

    (A) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with DLBCL (n = 57). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same 3 tumor samples. Original magnification, ×40; scale bars: 200 μm. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (B) qRT-PCR analysis in triplicate of samples from patients with DLBCL (n = 26) compared with normal lymphoid control tissue (n = 10). mRNA levels were normalized to β-actin and are presented as 2–ΔΔCt. Error bars represent the mean ± SEM. **P < 6.03 × 10–5 and *P = 0.014, by t test. (C) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in DLBCL (n = 319) compared with normal B cells (n = 49). Lines represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. **P < 2.2 × 10–16 and *P = 9.96 × 10–5, by t test. The data sets analyzed are listed in Supplemental Table 1. (D) Patient samples of DLBCL with low BCL-2 from the GSE31312 and GSE10846 data sets were each separated into 2 groups (BCL-W high and BCL-W low) on the basis of the median expression of BCL-W, and Kaplan-Meier analyses were performed. The P values in D were determined by log-rank test.
    Figure Legend Snippet: (A) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with DLBCL (n = 57). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same 3 tumor samples. Original magnification, ×40; scale bars: 200 μm. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (B) qRT-PCR analysis in triplicate of samples from patients with DLBCL (n = 26) compared with normal lymphoid control tissue (n = 10). mRNA levels were normalized to β-actin and are presented as 2–ΔΔCt. Error bars represent the mean ± SEM. **P < 6.03 × 10–5 and *P = 0.014, by t test. (C) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in DLBCL (n = 319) compared with normal B cells (n = 49). Lines represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. **P < 2.2 × 10–16 and *P = 9.96 × 10–5, by t test. The data sets analyzed are listed in Supplemental Table 1. (D) Patient samples of DLBCL with low BCL-2 from the GSE31312 and GSE10846 data sets were each separated into 2 groups (BCL-W high and BCL-W low) on the basis of the median expression of BCL-W, and Kaplan-Meier analyses were performed. The P values in D were determined by log-rank test.

    Techniques Used: Immunohistochemical staining, Whisker Assay, Staining, Quantitative RT-PCR, Microarray, Expressing

    (A) qRT-PCR analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and DLBCL cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.
    Figure Legend Snippet: (A) qRT-PCR analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and DLBCL cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.

    Techniques Used: Quantitative RT-PCR, Microarray, Expressing, Immunohistochemical staining, Whisker Assay, Staining, Western Blot, Purification

    (A) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with DLBCL (n = 57). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same 3 tumor samples. Original magnification, ×40; scale bars: 200 μm. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (B) qRT-PCR analysis in triplicate of samples from patients with DLBCL (n = 26) compared with normal lymphoid control tissue (n = 10). mRNA levels were normalized to β-actin and are presented as 2–ΔΔCt. Error bars represent the mean ± SEM. **P < 6.03 × 10–5 and *P = 0.014, by t test. (C) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in DLBCL (n = 319) compared with normal B cells (n = 49). Lines represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. **P < 2.2 × 10–16 and *P = 9.96 × 10–5, by t test. The data sets analyzed are listed in Supplemental Table 1. (D) Patient samples of DLBCL with low BCL-2 from the GSE31312 and GSE10846 data sets were each separated into 2 groups (BCL-W high and BCL-W low) on the basis of the median expression of BCL-W, and Kaplan-Meier analyses were performed. The P values in D were determined by log-rank test.
    Figure Legend Snippet: (A) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with DLBCL (n = 57). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same 3 tumor samples. Original magnification, ×40; scale bars: 200 μm. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (B) qRT-PCR analysis in triplicate of samples from patients with DLBCL (n = 26) compared with normal lymphoid control tissue (n = 10). mRNA levels were normalized to β-actin and are presented as 2–ΔΔCt. Error bars represent the mean ± SEM. **P < 6.03 × 10–5 and *P = 0.014, by t test. (C) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in DLBCL (n = 319) compared with normal B cells (n = 49). Lines represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. **P < 2.2 × 10–16 and *P = 9.96 × 10–5, by t test. The data sets analyzed are listed in Supplemental Table 1. (D) Patient samples of DLBCL with low BCL-2 from the GSE31312 and GSE10846 data sets were each separated into 2 groups (BCL-W high and BCL-W low) on the basis of the median expression of BCL-W, and Kaplan-Meier analyses were performed. The P values in D were determined by log-rank test.

    Techniques Used: Immunohistochemical staining, Whisker Assay, Staining, Quantitative RT-PCR, Microarray, Expressing

    Related Articles

    Quantitative RT-PCR:

    Article Title: Alternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer
    Article Snippet: For cDNA synthesis, 1 μg total RNA was reverse-transcribed using random hexamer, M-MLV reverse transcriptase (Promega, M170B), and RNase inhibitor (Enzynomics, M007S). .. The endometrial cancer cDNA array, (ORIGENE, EDRT102) and the breast cancer cDNA array (ORIGENE, BCRT101) were used to validate the PBRM1 E27 AS patterns. qRT-PCR was performed using the SYBR Green PCR Master Mix (GENETBIO, Q-9200) on an AriaMx real-time system (Agilent Technologies). .. PCR was performed using a hot-start PCR master mix (Bioneer, K-2630), followed by agarose gel electrophoresis.

    SYBR Green Assay:

    Article Title: Alternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer
    Article Snippet: For cDNA synthesis, 1 μg total RNA was reverse-transcribed using random hexamer, M-MLV reverse transcriptase (Promega, M170B), and RNase inhibitor (Enzynomics, M007S). .. The endometrial cancer cDNA array, (ORIGENE, EDRT102) and the breast cancer cDNA array (ORIGENE, BCRT101) were used to validate the PBRM1 E27 AS patterns. qRT-PCR was performed using the SYBR Green PCR Master Mix (GENETBIO, Q-9200) on an AriaMx real-time system (Agilent Technologies). .. PCR was performed using a hot-start PCR master mix (Bioneer, K-2630), followed by agarose gel electrophoresis.

    Polymerase Chain Reaction:

    Article Title: Alternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer
    Article Snippet: For cDNA synthesis, 1 μg total RNA was reverse-transcribed using random hexamer, M-MLV reverse transcriptase (Promega, M170B), and RNase inhibitor (Enzynomics, M007S). .. The endometrial cancer cDNA array, (ORIGENE, EDRT102) and the breast cancer cDNA array (ORIGENE, BCRT101) were used to validate the PBRM1 E27 AS patterns. qRT-PCR was performed using the SYBR Green PCR Master Mix (GENETBIO, Q-9200) on an AriaMx real-time system (Agilent Technologies). .. PCR was performed using a hot-start PCR master mix (Bioneer, K-2630), followed by agarose gel electrophoresis.

    other:

    Article Title: Krϋppel‐like factor 15 suppresses renal glomerular mesangial cell proliferation via enhancing P53 SUMO1 conjugation
    Article Snippet: Human full‐length SUMO1 cDNA (NM_003352.8) obtained from OriGene Technologies (Beijing, China) was inserted into pCMV6‐Entry plasmid (CAT#: RC200633).

    Article Title: DCAF14 promotes stalled fork stability to maintain genome integrity
    Article Snippet: Other siRNAs used in this study: DDB1 (L-012890), RADX (J-014634), RAD51 (J-003530-11), RAD51 (J-003530-12), MRE11 (J-009271-08), BLM (L-007287), SMARCAL1 (J-013058-06), CUL4A (L-012610), CUL4B (L-017965), DNA2 (pool of D-026431-03 and D-026431-04, siGENOME Dharmacon), ZRANB3 (D-010025-03, siGENOME Dharmacon), BRCA1 (J-003461), BRCA2-6 (SI02653434, QIAGEN) and All-stars negative control siRNA (1027280, QIAGEN).

    Functional Assay:

    Article Title: Cryo-EM reveals that iRhom2 restrains ADAM17 protease activity to control the release of growth factor and inflammatory signals
    Article Snippet: .. For functional studies, iRhom2 isoform 2 (aa 51–79 missing) was constructed based on the human iRhom2 isoform 1 cDNA (NM_024599.2; Origene, SC122961) and was cloned into pcDNA3.1(+) using In-Fusion HD Cloning Kit (Takara Bio, 639649) with 3x HA tag at the C terminus. .. Site-directed mutagenesis of the gene of interest was performed using the Cloned Pfu DNA polymerase AD (Agilent) according to the manufacturer’s instructions.

    Construct:

    Article Title: Cryo-EM reveals that iRhom2 restrains ADAM17 protease activity to control the release of growth factor and inflammatory signals
    Article Snippet: .. For functional studies, iRhom2 isoform 2 (aa 51–79 missing) was constructed based on the human iRhom2 isoform 1 cDNA (NM_024599.2; Origene, SC122961) and was cloned into pcDNA3.1(+) using In-Fusion HD Cloning Kit (Takara Bio, 639649) with 3x HA tag at the C terminus. .. Site-directed mutagenesis of the gene of interest was performed using the Cloned Pfu DNA polymerase AD (Agilent) according to the manufacturer’s instructions.

    Clone Assay:

    Article Title: Cryo-EM reveals that iRhom2 restrains ADAM17 protease activity to control the release of growth factor and inflammatory signals
    Article Snippet: .. For functional studies, iRhom2 isoform 2 (aa 51–79 missing) was constructed based on the human iRhom2 isoform 1 cDNA (NM_024599.2; Origene, SC122961) and was cloned into pcDNA3.1(+) using In-Fusion HD Cloning Kit (Takara Bio, 639649) with 3x HA tag at the C terminus. .. Site-directed mutagenesis of the gene of interest was performed using the Cloned Pfu DNA polymerase AD (Agilent) according to the manufacturer’s instructions.

    Cloning:

    Article Title: Cryo-EM reveals that iRhom2 restrains ADAM17 protease activity to control the release of growth factor and inflammatory signals
    Article Snippet: .. For functional studies, iRhom2 isoform 2 (aa 51–79 missing) was constructed based on the human iRhom2 isoform 1 cDNA (NM_024599.2; Origene, SC122961) and was cloned into pcDNA3.1(+) using In-Fusion HD Cloning Kit (Takara Bio, 639649) with 3x HA tag at the C terminus. .. Site-directed mutagenesis of the gene of interest was performed using the Cloned Pfu DNA polymerase AD (Agilent) according to the manufacturer’s instructions.

    Indirect Immunoperoxidase Assay:

    Article Title: E2-regulated transcriptome complexity revealed by long-read direct RNA sequencing: from isoform discovery to truncated proteins
    Article Snippet: .. IPA/FL ratio was normalized to normal breast cDNA sample (from OriGene TissueScan cDNA tissue array) (*** p < 0.001, one-way ANOVA), E. TCGA breast cancer dataset showing a positive correlation between the levels of the FL and IPA isoforms of TLE1 , F. Kaplan-Meier relapse-free survival curves comparing high- and low-ratio of ENST00000376463.2/ENST00000376499.7 (IPA/FL) TLE1 in TCGA LumA breast cancers (BRCA). ..

    Plasmid Preparation:

    Article Title: DCAF14 promotes stalled fork stability to maintain genome integrity.
    Article Snippet: Other siRNAs used in this study: DDB1 (L-012890), RADX (J-014634), RAD51 (J-003530-11), RAD51 (J-003530-12), MRE11 (J-009271-08), BLM (L-007287), SMARCAL1 (J-013058-06), CUL4A (L-012610), CUL4B (L-017965), DNA2 (pool of D-026431-03 and D-026431-04, siGENOME Dharmacon), ZRANB3 (D-010025-03, siGENOME Dharmacon), BRCA1 (J-003461), BRCA2-6 (SI02653434, QIAGEN) and All-stars negative control siRNA (1027280, QIAGEN). .. DCAF14 cDNA clone (RC217114) and the entry vector (PS100001) were purchased from Origene. .. Human RAD51 (Item ID = 125570) and RAD51K133R (Item ID = 125571) expressing vectors were purchased from Addgene.



    Similar Products

    90
    Promega control cdna sample
    Control Cdna Sample, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+cdna+sample/cdna+template/pm40537444-93-8-5
    Average 90 stars, based on 1 article reviews
    control cdna sample - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    92
    Bio-Rad cdna samples
    Cdna Samples, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+cdna+sample/Liquichek+Rheumatoid+Factor+Control/ppr0220352-259-36-15
    Average 92 stars, based on 1 article reviews
    cdna samples - by Bioz Stars, 2026-11
    92/100 stars
      Buy from Supplier

    90
    Dawley Inc control cdna samples
    Control Cdna Samples, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+cdna+sample/control+cdna+samples/pm27742580-102-13-24
    Average 90 stars, based on 1 article reviews
    control cdna samples - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    85
    Bio-Rad cdna 116 samples
    Cdna 116 Samples, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+cdna+sample/Liquichek+Anti-RNP+Control/pm28587460-76-1-20
    Average 85 stars, based on 1 article reviews
    cdna 116 samples - by Bioz Stars, 2026-11
    85/100 stars
      Buy from Supplier

    90
    OriGene tissuescan cdna arrays containing 26 samples from patients with dlbcl and 10 normal lymphoid tissue controls
    <t>(A)</t> <t>qRT-PCR</t> analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and <t>DLBCL</t> cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.
    Tissuescan Cdna Arrays Containing 26 Samples From Patients With Dlbcl And 10 Normal Lymphoid Tissue Controls, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+cdna+sample/Tissue+FFPE+Sections%2C+Lymphoid+tissue/pmc05272186-675-4-24
    Average 90 stars, based on 1 article reviews
    tissuescan cdna arrays containing 26 samples from patients with dlbcl and 10 normal lymphoid tissue controls - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    93
    Bio-Rad water baths cdna samples ssoadvancedtm sybr green supermix
    <t>(A)</t> <t>qRT-PCR</t> analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and <t>DLBCL</t> cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.
    Water Baths Cdna Samples Ssoadvancedtm Sybr Green Supermix, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+cdna+sample/Liquichek+Diabetes+Control/pmc04539021-713-24-33
    Average 93 stars, based on 1 article reviews
    water baths cdna samples ssoadvancedtm sybr green supermix - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    Bio-Rad quantitative pcr cdna samples
    <t>(A)</t> <t>qRT-PCR</t> analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and <t>DLBCL</t> cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.
    Quantitative Pcr Cdna Samples, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+cdna+sample/Lyphochek+Anemia+Control/pm24476075-76-0-41
    Average 94 stars, based on 1 article reviews
    quantitative pcr cdna samples - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    90
    CEM Corporation control cdna sample
    <t>(A)</t> <t>qRT-PCR</t> analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and <t>DLBCL</t> cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.
    Control Cdna Sample, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+cdna+sample/control+cdna+sample/pm15735722-175-6-11
    Average 90 stars, based on 1 article reviews
    control cdna sample - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) qRT-PCR analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and DLBCL cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.

    Journal: The Journal of Clinical Investigation

    Article Title: BCL-W has a fundamental role in B cell survival and lymphomagenesis

    doi: 10.1172/JCI89486

    Figure Lengend Snippet: (A) qRT-PCR analysis (in triplicate) of samples from patients with BL (n = 15) compared with normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4, by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression was assessed by Western blotting for the indicated proteins in BL and DLBCL cell lines. Controls included tissue from 2 human spleens and purified B cells from human peripheral blood.

    Article Snippet: For qRT-PCR analysis of DLBCL, TissueScan cDNA arrays containing 26 samples from patients with DLBCL and 10 normal lymphoid tissue controls were obtained from OriGene.

    Techniques: Quantitative RT-PCR, Microarray, Expressing, Immunohistochemical staining, Whisker Assay, Staining, Western Blot, Purification

    (A) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with DLBCL (n = 57). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same 3 tumor samples. Original magnification, ×40; scale bars: 200 μm. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (B) qRT-PCR analysis in triplicate of samples from patients with DLBCL (n = 26) compared with normal lymphoid control tissue (n = 10). mRNA levels were normalized to β-actin and are presented as 2–ΔΔCt. Error bars represent the mean ± SEM. **P < 6.03 × 10–5 and *P = 0.014, by t test. (C) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in DLBCL (n = 319) compared with normal B cells (n = 49). Lines represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. **P < 2.2 × 10–16 and *P = 9.96 × 10–5, by t test. The data sets analyzed are listed in Supplemental Table 1. (D) Patient samples of DLBCL with low BCL-2 from the GSE31312 and GSE10846 data sets were each separated into 2 groups (BCL-W high and BCL-W low) on the basis of the median expression of BCL-W, and Kaplan-Meier analyses were performed. The P values in D were determined by log-rank test.

    Journal: The Journal of Clinical Investigation

    Article Title: BCL-W has a fundamental role in B cell survival and lymphomagenesis

    doi: 10.1172/JCI89486

    Figure Lengend Snippet: (A) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from patients with DLBCL (n = 57). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same 3 tumor samples. Original magnification, ×40; scale bars: 200 μm. For the box and whisker plots, the box represents the 25th and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (B) qRT-PCR analysis in triplicate of samples from patients with DLBCL (n = 26) compared with normal lymphoid control tissue (n = 10). mRNA levels were normalized to β-actin and are presented as 2–ΔΔCt. Error bars represent the mean ± SEM. **P < 6.03 × 10–5 and *P = 0.014, by t test. (C) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in DLBCL (n = 319) compared with normal B cells (n = 49). Lines represent the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. **P < 2.2 × 10–16 and *P = 9.96 × 10–5, by t test. The data sets analyzed are listed in Supplemental Table 1. (D) Patient samples of DLBCL with low BCL-2 from the GSE31312 and GSE10846 data sets were each separated into 2 groups (BCL-W high and BCL-W low) on the basis of the median expression of BCL-W, and Kaplan-Meier analyses were performed. The P values in D were determined by log-rank test.

    Article Snippet: For qRT-PCR analysis of DLBCL, TissueScan cDNA arrays containing 26 samples from patients with DLBCL and 10 normal lymphoid tissue controls were obtained from OriGene.

    Techniques: Immunohistochemical staining, Whisker Assay, Staining, Quantitative RT-PCR, Microarray, Expressing